Regression of Died at therapy 7 years before lung metastases 18 months for hyperthyroidism Other metastases Metastases mediastinum fatal and lung appears to be a solitary one expanding and destroying the clavicle, and it now takes up very much more iodine after a therapeutic ablation of the thyroid gland. In fact, its uptake of iodine has risen from 1 % prior to ablation to 13-5 % following it. Even so, the mass is of such a size that an effective dose from 131I cannot be expected and he is being treated by a combination of L3I1 therapy and supervoltage X-rays.
My conclusion is that we can take little account of survival statistics alone in assessing the value of radiotherapy or surgery in this diseas. Far more convincing than statistics is the visible disappearance of growth, and especially when that growth is causing pressure symptoms which threaten the patient's very existence. Team work between surgeon, radiotherapist and pathologist concerned with the case is of first importance, and all our resources must be brought to bear against the relentless growth once it is diagnosed. Often it will be a matter of control rather than cure.
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During the period 1950-1956 a total of 102 patients with thyroid carcinoma were referred to the Radiotherapy Department at Hammersmith Hospital for some form of radiotherapy. The majority were treated by external irradiation. 25 patients were given at least one therapeutic dose of radioiodine, but only 14 had metastases which were clearly shown to concentrate radioiodine.
It is convenient to consider the treatment of thyroid carcinoma from the pathological standpoint. The most satisfactory classification of malignant tumours of the thyroid is that of Warren and Meissner (1953) who distinguish three main types, papillary, follicular and anaplastic. In practice thyroid carcinomas frequently show a variety of histological patterns, Proceedings of the Royal Society of Medimne 14 but it is helpful when discussing treatment to try to allocate a thyroid carcinoma to one of the three main groups according to the predominant histological picture. The histology of the tumours in all patients referred for radiotherapy is shown in Table I . It will be noted that there are rather more patients with anaplastic tumours and rather fewer with papillary tumours than might be expected in an unselected series of patients with thyroid cancer. Radioiodine is most likely to be of use in patients with follicular carcinoma of the thyroid. It should perhaps be emphasized that it does not in any way compete with surgery as the primary method of treatment and in operable cases excision of the tumour together with the whole of the normal thyroid gland is the proper method of treatment. About half of the patients with follicular tumours already have distant metastases when first seen, and it has been noted that metastases occur most frequently in patients with well differentiated tumours. Any patient who has metastases from a follicular carcinoma of the thyroid should therefore be considered as a possible candidate for treatment with radioiodine.
It may be possible to demonstrate function in tumour tissue before the thyroid has been removed. More commonly thyroid ablation must first be carried out since normal thyroid tissue invariably concentrates iodine far more efficiently than even highly differentiated tumour tissue. Evidence of uptake of radioiodine in tumour tissue may be obtained with the thyroid still in situ either by external counting methods or by autoradiography. The technique of profile counting which has been described by Pochin etal. (1952) is a convenient method of carrying out in vivo studies and is particularly useful when serial measurements are made. Alternatively when the apparatus necessary for profile counting is not available localisation studies can be quite satisfactorily carried out with a Geiger or scintillation counter suitably collimated for directional scanning.
When a metastasis is accessible to drill or needle biopsy or a lymph node can be excised, a specimen of tumour tissue may be obtained after giving a tracer dose of radioiodine and examined both for its histology and by autoradiography. This is undoubtedly the most sensitive and discriminating method of detecting uptake of radioiodine in tumour tissue.
Although thyroid tumours miay concentrate iodine while the thyroid gland is still in situ, metastases cannot be effectively treated with radioiodine until the thyroid has first been ablated. Surgical ablation is the method of choice but when the primary tumour is considered to be locally inoperable or the general condition of the patient is poor the thyroid may be destroyed by radioiodine; a dose of 50-100 millicuries is usually sufficient. In general, patients most likely to be suitable for treatment with radioiodine are those with metastases from well-differentiated follicular carcinoma of the thyroid. Although the histological appearance of the primary tumour gives the best indication of whether the metastases are likely to function or not, the functional behaviour of thyroid tumours cannot always be related to their structure. In this series of patients with functioning metastases, two had papillary carcinomas of the thyroid; another who had a poorly differentiated primary adenocarcinoma of the thyroid developed a secondary deposit in the pelvis which was well differentiated and concentrated iodine. This is contrary to the usual behaviour of metastases w.,ich tend to be less differentiated than the parent tumour. The remaining patients all had differentiated follicular carcinomas which were forming colloid. In one instance a rib metastasis was so well differentiated that it was impossible on histological grounds to distinguish it from normal thyroid tissue, an example of what used to be called "benign metastasizing struma". On the other hand, in several patients with differentiated follicular carcinomas it proved impossible to promote any uptake in metastatic tissue even after thyroid ablation and the induction of myxcedema. From the foregoing it will be apparent that the selection of patients for treatment with radioiodine is not easy, since it is impossible to predict with any degree of certainty whether or not thyroid ablation is likely to have the desired effect of inducing uptake in metastatic tissue. It is, however, extremely unlikely that anaplastic tumours will respond to treatment with radioiodine and when skeletal deposits from this type of tumour give rise to symptoms they are best treated by external irradiation. 21 patients with metastases were selected for treatment with radioiodine. Before thyroidectomy evidence of uptake in tumour tissue was obtained in 9 patients. After thyroid ablation a further 5 patients were shown to have functioning tumours, but in the remaining 7 patients no uptake could be demonstrated in metastatic tissue. After thyroid ablation the patients are allowed to become myxcedematous. The signs and symptoms of myxoedema begin to appear about six to eight weeks after operation and further tests for radioiodine uptake may be made at about this time. There may at this stage be sufficient uptake to warrant giving a therapeutic dose or alternatively it may be possible to enhance uptake either by giving an antithyroid drug or by the injection of thyrotrophic hormone (T.S.H.). Both methods have certain advantages.
Both growth and function in functioning thyroid carcinomas can be modified by the action of T.S.H. Thus a high blood level of T.S.H. will increase the rate of accumulation of iodine by tumour tissue. Conversely if the secretion of T.S.H. by the pituitary is inhibited by the administration of thyroid hormone, iodine uptake may be abolished and restraint of growth or even regression may occur. The blood level of T.S.H. may be raised either by the injection of exogenous T.S.H. or by inducing myxoedema and thus stimulating the pituitary to increase the output of endogenous T.S.H. If a patient becomes grossly myxcedematous following thyroid ablation it is unlikely that any useful purpose is served by giving an antithyroid drug.
If on the other hand metastatic tissue is producing sufficient hormone to maintain the patient in a nearly euthyroid or only slightly hypothyroid condition then the tumour will not be subjected to the maximum stimulation by T.S.H. and an antithyroid drug given for a period of a month or so is likely to increase further the uptake of radioiodine and ensure the optimum utilization of a therapeutic dose. Most of our patients had tumours which were physiologically efficient and in these circumstances an antithyroid drug has usually been given with distinct advantage. One disadvantage of using an antithyroid drug to increase uptake is that growth of the tumour is also stimulated and where, for example, a deposit is already causing compression of a nerve or nerve root, further prolonged stimulation of growth may be strongly contra-indicated. In circumstances such as this it may be preferable as an alternative to stimulate uptake by the injection of T.S.H. One or several intramuscular injections may be given. The maximum effect on the uptake of radioiodine will occur twenty-four hours after the last injection. It might seem that the injection of non-physiological doses of T.S.H. would be preferable to the use of an antithyroid drug for increasing uptake in tumour tissue. It does not involve the delay in treatment that is inevitable when an antithyroid drug is used and it obviates the need for making the patient myxoedematous. It would of course be extremely difficult to make a valid comparison of the two methods but in practice T.S.H. seems to be the less reliable of the two.
Dosage in radioiodine therapy is quite empirical. Our usual practice is to give a dose of 150-200 mc. Symptoms of radiation sickness may develop after doses of this order but they are usually quite mild. Further treatment is given at intervals of three to four months so long as any uptake of radioiodine by tumour tissue remains. Two or three doses have usually been required but in no case has the total cumulative dose exceeded 600 mc. It has been found that progressively smaller amounts of radioiodine are concentrated by tumour tissue after each therapeutic dose.
Patients who have been treated with radioiodine should always be maintained on a full replacement dose of thyroid hormone both in the intervals between treatment and after their treatment is completed. It is probably best to aim at the highest dose which can be tolerated without producing any symptoms of thyroid intoxication and it must be emphasized that this is an important part of the treatment of patients with thyroid carcinoma. Balme (1954) described regression of secondary deposits in the lungs in a patient with a thyroid carcinoma who was treated with thyroxine. The management of patients who are undergoing treatment with radioiodine is greatly facilitated and the periods of disability due to hypothyroidism are reduced if triiodothyronine is used instead of thyroxine for maintenance therapy. When patients are maintained on thyroxine it has to be stopped about a month before radioiodine tests are carried out. With triiodothyronine which has a rapid metabolic effect and a shorter duration of action than thyroxine it is only necessary to wait about two weeks before carrying out radioiodine tests. Triiodothyronine may be started again twenty-four hours after a therapeutic dose with rapid relief of the myxoedematous state.
There are two serious complications which may rarely occur after radioiodine therapy, namely radiation damage to the lungs and radiation damage to the bone-marrow. The occurrence of radiation pneumonitis and fibrosis following radioiodine was reported recently by Rall et al. (1957) . They noted this complication only in patients with multiple or diffuse metastatic involvement of the lungs. One of our patients with multiple deposits in the lungs was given three therapeutic doses of radioiodine, receiving in all 450 mc. She died two years later from cor pulmonale and at autopsy was found to have marked pulmonary fibrosis; it is probable that this was attributable to radiation. 30
Therapeutic doses of 150-200 mc. usually have a slight temporary effect on the peripheral blood count producing a fall in the number of circulating platelets and lymphocytes and the polymorphonuclear leucocytes may also be affected. More severe changes are liable to occur in patients who have multiple deposits in bone, and persistent leucopenia which may be of sufficient severity to interfere with further treatment may occur. We have had one case of severe bone-marrow depression after a single therapeutic dose. The patient who was thyrotoxic when first seen had pulmonary and skeletal metastases. When the thyrotoxicosis had been controlled with carbimazole a total thyroidectomy was performed. Carbimazole was continued for a few weeks post-operatively and a therapeutic dose of 200 mc. of radioiodine was then given. Initially his general condition improved remarkably and pain which had previously been severe was relieved, but four weeks later his condition suddenly deteriorated and he developed petechim and spontaneous hemorrhages. Examination of the bone-marrow showed almost complete aplasia. The effect of radioiodine on the peripheral blood count is shown in Fig. 1 . He recovered from this episode but later the metastases became active and he again became thyrotoxic. He was eventually found at autopsy to have extensive skeletal deposits. Carcinoma of the thyroid is sometimes found in association with thyrotoxicosis but it is most unusual for metastatic tissue to cause hyperthyroidism; for this to occur a relatively enormous amount of neoplastic tissue must be present.
Firm conclusions cannot be drawn on the results of treatment from such a small series as this, especially when the natural history of the disease is so variable. 2 patients with skeletal metastases have survived for more than five years; another with multiple pulmonary deposits died seven years after treatment. On the other hand some patients who were in a very poor condition and had multiple metastases when first seen did not survive for more than a few months.
It may be asked whether radioiodine can be considered as a curative form of treatment. It would seem that in patients who have a limited number of metastases radical treatment should be given and an attempt made to eradicate the disease. Even if this is not successful, at the least very long-term palliation can be achieved.
